SCHEMBL1711248

SCHEMBL1711248

CC(C)(C)OC(=O)N1CC2C=C[C@H]1C2

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.42
CHRM1 P11229 1/20 0.42
CHRM3 P20309 1/20 0.42
NR1H2 P55055 1/20 0.40
HSD11B1 P28845 2/20 0.38
POLB P06746 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C19 P33261 1/20 0.36
AR P10275 1/20 0.34
UCHL1 P09936 1/20 0.34
USP2 O75604 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CTSK P43235 1/20 0.34
HSD17B10 Q99714 1/20 0.34
NFKB1 P19838 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1711809 1.00 CHRM2 (0.42) CHRM2CHRM1CHRM3NR1H2HSD11B1
SCHEMBL26046497 1.00 CHRM2 (0.42) CHRM2CHRM1CHRM3NR1H2HSD11B1
SCHEMBL12275013 1.00 CHRM2 (0.42) CHRM2CHRM1CHRM3NR1H2HSD11B1
SCHEMBL1711301 1.00 CHRM2 (0.42) CHRM2CHRM1CHRM3NR1H2HSD11B1
SCHEMBL6097554 1.00 CHRM2 (0.42) CHRM2CHRM1CHRM3NR1H2HSD11B1
SCHEMBL24267673 0.76 HSD11B1 (0.41) CHRM2CHRM1CHRM3NR1H2HSD11B1
SCHEMBL10516953 0.75 PDE4B (0.40) CHRM2CHRM1CHRM3NR1H2HSD11B1
SCHEMBL12955029 0.73 CHRM2 (0.40) CHRM2CHRM1CHRM3NR1H2HSD11B1
SCHEMBL12954976 0.73 CHRM2 (0.40) CHRM2CHRM1CHRM3NR1H2HSD11B1
SCHEMBL25201897 0.73 CHRM2 (0.44) CHRM2CHRM1CHRM3NR1H2USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110263629-A1 AMIDES OF DIAZABICYCLOOCTANES AND USES THEREOF TARGACEPT, INC. (US) 2011-10-27 US disclosed
EP-2344496-A1 AMIDES OF DIAZABICYCLOOCTANES AND USES THEREOF Targacept Inc. (US) 2011-07-20 EP disclosed
WO-2010028033-A1 AMIDES OF DIAZABICYCLOOCTANES AND USES THEREOF TARGACEPT, INC. (US) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263629-A1 AMIDES OF DIAZABICYCLOOCTANES AND USES THEREOF CHRNA2, CHRNA10, CHRNA5 CHRM2 19/4885CHRM1 20/4885CHRM3 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.